Endocyte Secures DOXIL(R) Supply to Support Ongoing Phase 3 PROCEED Trial in Ovarian Cancer .
WEST LAFAYETTE, Ind., Aug 2, 2012 (GlobeNewswire via COMTEX) -- Endocyte, Inc., /quotes/zigman/119422/quotes/nls/ecyt ECYT +3.55% , a biopharmaceutical company developingr .
targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company has secured DOXIL(R) (doxorubicin HCl liposome injection) supply from Janssen Products, LP, to supplement existing supply already in place to support the ongoing Phase 3 PROCEED trial in ovarian cancer. The PROCEED trial compares vintafolide in combination with DOXIL versus DOXIL alone for the treatment of folate-receptor positive platinum resistant ovarian cancer.
"The supply of DOXIL announced today adds to our flexibility in meeting the ongoing needs of the PROCEED trial so we may continue to enroll patients without interruption," said Ron Ellis, president and CEO at Endocyte. "We will continue to work closely with Janssen to ensure that DOXIL supply allows the PROCEED trial to remain on schedule. Current estimates call for new supply of DOXIL to be available by the end of the year."
...